This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
With cannabis-derived products outpacing the existing science and imposing massive health concerns, in October 2021 the FDA issued a “Cannabis-derived products data acceleration plan” to detect safety signals and accelerate research studies.
The study compared the pharmacokinetic profiles of three of Caliper's proprietary soluble CBD formats against two control formats: oil-based CBD tincture and unemulsified CBD isolate.
Charlotte's Web Holdings, Inc.’s CW Labs science division and the University at Buffalo's Center for Integrated Global Biomedical Sciences are collaborating to advance hemp cannabinoid science through a research program that provides a better understanding of the therapeutic uses and safety of cannabinoids.
Health Canada has granted BevCanna Enterprises Inc. a research license to study the stability and homogeneity of water-soluble cannabinoid infusions in water-based beverages.